Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00712855 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | PHASE1 | COMPLETED | 23 | — | — | Jun 1, 2008 | Aug 1, 2012 | Oct 30, 2012 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | mapatumumab and sorafenib |
| Name | Type | Description |
|---|---|---|
| mapatumumab | BIOLOGICAL | 3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle |
| sorafenib | DRUG | 400 mg orally, twice a day continuously in each cycle |
Inclusion Criteria: * Moderate liver disease * Test positive for hepatitis B surface antigen or hepatitis C antibody * Locally advanced unresectable/untransplantable or metastatic hepatocellular carcinoma * Age 18 years or older Exclusion Criteria: * Received investigational (not yet approved by ...